insights_auto
Waarom is ALMKT gedaald 3,24%?
Meer informatiechevron_right
ALMKT:EPA
Mauna Kea Technologies SA
€ 0,11
arrow_downward
-3,24%(-0,0036) 1D
20 okt, 17:35:27 GMT+2 · EUR
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor ALMKT genereren…
Openen
€ 0,11
Hoog
€ 0,11
Laag
€ 0,11
Beursw.
21,24 mln.
Gem. vol.
448,38K
Volume
296,01K
Koers/winst-verhouding
0,92
52 wk hoog
€ 0,23
52 wk laag
€ 0,07
WPA
€ 0,12
Uitstaande aandelen
195,26 mln.
Aantal medewerkers
56
Openen
€ 0,11
Hoog
€ 0,11
Laag
€ 0,11
Beursw.
21,24 mln.
Gem. vol.
448,38K
Volume
296,01K
Koers/winst-verhouding
0,92
52 wk hoog
€ 0,23
52 wk laag
€ 0,07
WPA
€ 0,12
Uitstaande aandelen
195,26 mln.
Aantal medewerkers
56
Nieuwsartikelen
Van webbronnen en nieuwspartners
Yahoo Finance
·
4 uur geleden
Mauna Kea Technologies Reports Nine-Month 2026 Sales of €4.4 Million, Up 24% at Constant Exchange Rates
TradingView
·
4 uur geleden
ALMKT: 9M sales rose 24% CER, led by international growth and CellTolerance
Profiel
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
Over Mauna Kea Technologies SA